Latest Insider Transactions at Syros Pharmaceuticals, Inc. (SYRS)
This section provides a real-time view of insider transactions for Syros Pharmaceuticals, Inc. (SYRS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Syros Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Syros Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Payment of exercise price or tax liability
|
Direct |
3,100
-6.23%
|
$6,200
$2.1 P/Share
|
|
Sep 30
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.73%
|
-
|
|
Sep 16
2024
|
Richard A Young |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+20.0%
|
-
|
|
Sep 16
2024
|
Srinivas Akkaraju |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+22.23%
|
-
|
|
Sep 12
2024
|
Jason Haas Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
45,344
+26.69%
|
$45,344
$1.68 P/Share
|
|
Sep 11
2024
|
Conley Chee President & CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+28.98%
|
$50,000
$1.71 P/Share
|
|
Sep 11
2024
|
Jason Haas Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
19,293
+19.59%
|
$19,293
$1.58 P/Share
|
|
Sep 10
2024
|
Conley Chee President & CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+40.82%
|
$50,000
$1.51 P/Share
|
|
Sep 10
2024
|
Jason Haas Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
35,363
+37.12%
|
$35,363
$1.55 P/Share
|
|
Jun 28
2024
|
Richard A Young |
SELL
Open market or private sale
|
Direct |
34,837
-81.32%
|
$174,185
$5.12 P/Share
|
|
Jun 05
2024
|
Peter Wirth |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+20.0%
|
-
|
|
Jun 05
2024
|
Marsha Fanucci |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+20.0%
|
-
|
|
Jun 05
2024
|
Andrew M. Oh |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+20.0%
|
-
|
|
Jun 05
2024
|
Sue Gail Eckhardt |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+20.0%
|
-
|
|
Jun 05
2024
|
Timothy Tyson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+10.76%
|
-
|
|
Jun 05
2024
|
Richard A Young |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+8.54%
|
-
|
|
Jun 05
2024
|
Nancy A Simonian |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+2.86%
|
-
|
|
Jun 01
2024
|
Srinivas Akkaraju |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+37.5%
|
-
|
|
Jun 01
2024
|
Deborah Dunsire |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+25.0%
|
-
|
|
Apr 03
2024
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,451
-100.0%
|
$41,804
$4.95 P/Share
|
|
Apr 02
2024
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
150
-1.42%
|
$600
$4.98 P/Share
|
|
Apr 01
2024
|
Nancy A Simonian |
SELL
Payment of exercise price or tax liability
|
Direct |
14,052
-9.64%
|
$70,260
$5.12 P/Share
|
|
Apr 01
2024
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,218
-14.32%
|
$21,090
$5.12 P/Share
|
|
Apr 01
2024
|
Jason Haas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,732
-16.16%
|
$23,660
$5.12 P/Share
|
|
Apr 01
2024
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,732
-30.86%
|
$23,660
$5.12 P/Share
|
|
Apr 01
2024
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,500
-13.46%
|
$17,500
$5.12 P/Share
|
|
Mar 31
2024
|
Nancy A Simonian |
BUY
Exercise of conversion of derivative security
|
Direct |
45,566
+13.35%
|
-
|
|
Mar 31
2024
|
Kristin Stephens Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,666
+19.24%
|
-
|
|
Mar 31
2024
|
Jason Haas Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,333
+21.21%
|
-
|
|
Mar 31
2024
|
David Roth Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,333
+48.26%
|
-
|
|
Mar 31
2024
|
Conley Chee President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,666
+21.61%
|
-
|
|
Mar 28
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Payment of exercise price or tax liability
|
Direct |
7,046
-15.05%
|
$35,230
$5.59 P/Share
|
|
Mar 27
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+32.47%
|
-
|
|
Dec 21
2023
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
904,977
+33.62%
|
$3,619,908
$4.42 P/Share
|
|
Dec 12
2023
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,287
-100.0%
|
$25,148
$4.95 P/Share
|
|
Dec 06
2023
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,287
-50.0%
|
$18,861
$3.95 P/Share
|
|
Nov 01
2023
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,004
-32.73%
|
$12,008
$2.22 P/Share
|
|
Nov 01
2023
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,676
-26.44%
|
$11,352
$2.22 P/Share
|
|
Nov 01
2023
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,301
-33.38%
|
$12,602
$2.22 P/Share
|
|
Nov 01
2023
|
Jason Haas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,301
-31.11%
|
$12,602
$2.22 P/Share
|
|
Nov 01
2023
|
Nancy A Simonian |
SELL
Payment of exercise price or tax liability
|
Direct |
13,401
-11.8%
|
$26,802
$2.22 P/Share
|
|
Oct 31
2023
|
Conley Chee President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+48.1%
|
-
|
|
Oct 31
2023
|
Kristin Stephens Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+44.2%
|
-
|
|
Oct 31
2023
|
David Roth Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,875
+50.0%
|
-
|
|
Oct 31
2023
|
Jason Haas Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,875
+48.24%
|
-
|
|
Oct 31
2023
|
Nancy A Simonian |
BUY
Exercise of conversion of derivative security
|
Direct |
40,125
+26.11%
|
-
|
|
Oct 19
2023
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Payment of exercise price or tax liability
|
Direct |
6,897
-22.11%
|
$13,794
$2.1 P/Share
|
|
Oct 11
2023
|
Gerald E Quirk Chief Legal & Compliance Offic |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+41.9%
|
-
|
|
Sep 16
2023
|
Srinivas Akkaraju |
BUY
Exercise of conversion of derivative security
|
Direct |
2,666
+50.0%
|
-
|
|
Sep 16
2023
|
Mark J Alles Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,666
+42.1%
|
-
|